Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9-Reference-Cited by-同舟云学术

Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9

Published:2017-07-27 Issue:7 Volume:12 Page:e0180869
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Romagnuolo Rocco,Scipione Corey A.,Marcovina Santica M.,Gemin Matthew,Seidah Nabil G.,Boffa Michael B.,Koschinsky Marlys L.^ORCID

Funder

Regeneron Pharmaceuticals

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference57 articles.

1. Genetic variants associated with Lp(a) lipoprotein level and coronary disease;R Clarke;N Engl J Med,2009

2. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction;PR Kamstrup;JAMA,2009

3. Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum;ML Koschinsky;Endocrinol Metab Clin North Am,2014

4. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen;JW McLean;Nature,1987

5. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms;YY van der Hoek;Hum Mol Genet,1993

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside;Signal Transduction and Targeted Therapy;2024-01-08

2. Plasminogen Receptors Promote Lipoprotein(a) Uptake by Enhancing Surface Binding and Facilitating Macropinocytosis;Arteriosclerosis, Thrombosis, and Vascular Biology;2023-10

3. Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor;Pharmacological Research;2023-08

4. Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials;Endokrynologia Polska;2023-06-26

5. Effects of Xuezhikang versus Pravastatin on Triglyceride Level in Patients with T2DM and Dyslipidemia: Study Protocol for a Multicenter Randomized Controlled Trial;Current Vascular Pharmacology;2023-05